Friends of Cancer Research Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

WASHINGTON--The national cancer community has joined together to create a nonprofit organization, the Friends of Cancer Research, to commemorate the 25th anniversary of the National Cancer Act through a public awareness and education campaign on the importance of cancer research.

WASHINGTON--The national cancer community has joined togetherto create a nonprofit organization, the Friends of Cancer Research,to commemorate the 25th anniversary of the National Cancer Actthrough a public awareness and education campaign on the importanceof cancer research.

The Friends board includes members of the groups most active inthe fight against cancer, including the National Cancer AdvisoryBoard, National Coalition for Cancer Survivorship, Presidents'Cancer Panel, ASCO, AACR, National Alliance of Breast Cancer Organizations,Oncology Nursing Society, National Coalition for Cancer Research,American Cancer Society, and a number of prominent US cancer centers.

The campaign will include events and public forums at which RichardKlausner, MD, director of the National Cancer Institute, and othersenior officials will report to the American people on the stateof cancer research. These events will also provide an opportunityfor the cancer community and other interested parties to identifytheir most important research priorities for the coming years.

Recent Videos
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
Related Content